The Quebec government has launched a reimbursement program to cover Sculptra treatments for facial lipodystrophy caused by first-generation HIV medications, according to an investigative report by Le Devoir. The initiative provides a recurring annual envelope of approximately $500,000 to cover the collagen-stimulating dermal filler for patients who used early antiretroviral therapies for at least six months.
Understanding Facial Lipodystrophy and First-Generation HIV Therapies
Facial lipodystrophy is a condition characterized by severe facial wasting and the abnormal loss or accumulation of fat beneath the skin. According to Dr. François Laplante of the Quartier Latin medical clinic in Montreal, the condition is associated with antiretroviral medications introduced in the late 1990s. While these early drug regimens saved countless lives during the height of the AIDS epidemic, they left enduring physical changes that persist decades later for many patients, leading to visible stigma and social isolation.
Until the launch of this new program, patients requiring Sculptra had to pay out of pocket for the procedures, with total costs frequently reaching thousands of dollars per patient, as noted by Dr. Laplante. The newly implemented program fully covers the medical injections for eligible individuals who endured these legacy treatments.
In a public report, National Complaints and Services Quality Commissioner Martine Gosselin noted that the government originally announced plans to cover the treatment through the Régie de l’assurance maladie du Québec (RAMQ) back in 2019, with a scheduled launch date of 2020. By July 2025, Gosselin reported that no formal initiative had materialized to give patients access through public-system physicians, describing the delay as a breach of fundamental rights affecting patients’ physical dignity and mental health.
Regulatory Obstacles and Administrative Solutions
According to the Quebec Ministry of Health and Social Services (MSSS), the primary hurdle delaying the program’s implementation involved the regulatory classification of Sculptra. Health Canada classifies the product as a medical device rather than a pharmaceutical drug, which prevented it from being added to the standard provincial list of covered medications.
To bypass this regulatory barrier, the MSSS developed a dedicated clinical management and reimbursement framework instead of standard drug list integration. Additionally, the ministry finalized an agreement with the Fédération des médecins omnipraticiens du Québec (FMOQ) to establish a specific fee code for physicians administering Sculptra injections for HIV-related lipodystrophy.
Keep reading